| 1 | EPCAM, HRAS, ZEB1
|
| Cytosolic EpCAM cooperates with H-Ras to regulate epithelial to mesenchymal transition through ZEB1
|
| Omar FA, Brown TC, Gillanders WE, Fleming TP, Smith MA, Bremner RM, Sankpal NV.
|
| PLoS One. May 16;18(5):e0285707. doi: 10.1371/journal.pone.0285707. 2023
|
| 2 | HRAS, KRAS, LZTR1, MRAS, NRAS
|
| LZTR1 facilitates polyubiquitination and degradation of RAS-GTPases.
|
| Abe T, Umeki I, Kanno SI, Inoue SI, Niihori T, Aoki Y.
|
| Cell Death Differ. Mar;27(3):1023-1035. doi: 10.1038/s41418-019-0395-5. Epub 2019 Jul 23 2020
|
| 3 | HRAS, KRAS, LZTR1
|
| LZTR1 is a regulator of RAS ubiquitination and signaling.
|
| Bigenzahn JW, Collu GM, Kartnig F, Pieraks M, Vladimer GI, Heinz LX, Sedlyarov V, Schischlik F, Fauster A, Rebsamen M, Parapatics K, Blomen VA, Müller AC, Winter GE, Kralovics R, Brummelkamp TR, Mlodzik M, Superti-Furga G.
|
| Science Dec 7;362(6419):1171-1177. doi: 10.1126/science.aap8210. Epub 2018 Nov 15 2018
|
| 4 | CIB1, HRAS, PAPSS1
|
| CIB1 contributes to oncogenic signalling by Ras via modulating the subcellular localisation of sphingosine kinase 1.
|
| Zhu W, Gliddon BL, Jarman KE, Moretti PAB, Tin T, Parise LV, Woodcock JM, Powell JA, Ruszkiewicz A, Pitman MR, Pitson SM.
|
| Oncogene 36(18):2619-2627. doi: 10.1038/onc.2016.428. Epub 2016 Dec 12.
2017
|
| 5 | CIP2A, HRAS
|
| CIP2A cooperates with H-Ras to promote epithelial-mesenchymal transition in cervical-cancer progression.
|
| Wu Y, Gu TT, Zheng PS.
|
| Cancer Lett 356(2 Pt B):646-55. doi: 10.1016/j.canlet.2014.10.013.
2015
|
| 6 | HRAS, ING4, TDG
|
| Oncogenic Ras suppresses ING4-TDG-Fas axis to promote apoptosis resistance.
|
| Sun J, Shen Q, Lu H, Jiang Z, Xu W, Feng L, Li L, Wang X, Cai X, Jin H.
|
| Oncotarget 6(39):41997-2007. doi: 10.18632/oncotarget.6015.
2015
|
| 7 | HRAS, NOS3
|
| Endomembrane H-Ras controls vascular endothelial growth factor-induced nitric-oxide synthase-mediated endothelial cell migration.
|
| Haeussler DJ, Pimentel DR, Hou X, Burgoyne JR, Cohen RA, Bachschmid MM.
|
| J Biol Chem 288(21):15380-9. doi: 10.1074/jbc.M112.427765. Epub 2013 Apr 2.
2013
|
| 8 | COSTS, HRAS
|
| Two cases with severe lethal course of Costello syndrome associated with HRAS p.G12C and p.G12D.
|
| Lorenz S, Petersen C, Kordaß U, Seidel H, Zenker M, Kutsche K.
|
| Eur J Med Genet 55(11):615-9. doi: 10.1016/j.ejmg.2012.07.007. Epub 2012 Aug 7.
2012
|
| 9 | HRAS, TP53BP2
|
| Autophagic activity dictates the cellular response to oncogenic RAS.
|
| Wang Y, Wang XD, Lapi E, Sullivan A, Jia W, He YW, Ratnayaka I, Zhong S, Goldin RD, Goemans CG, Tolkovsky AM, Lu X.
|
| Proc Natl Acad Sci U S A 109(33):13325-30. doi: 10.1073/pnas.1120193109. Epub 2012 Jul 30.
2012
|
| 10 | HRAS
|
| Oncogene Ras/phosphatidylinositol 3-kinase signaling targets histone H3 acetylation at lysine 56.
|
| Liu Y, Wang DL, Chen S, Zhao L, Sun FL.
|
| J Biol Chem 287(49):41469-80. doi: 10.1074/jbc.M112.367847. Epub 2012 Sep 16.
2012
|
| 11 | HRAS, KRAS
|
| Interplay between oncogenic K-Ras and wild-type H-Ras in Caco2 cell transformation.
|
| Ikonomou G, Kostourou V, Shirasawa S, Sasazuki T, Samiotaki M, Panayotou G.
|
| J Proteomics 75(17):5356-69. doi: 10.1016/j.jprot.2012.06.038. Epub 2012 Jul 16.
2012
|
| 12 | HRAS
|
| Methylation pattern of oncogene HRAS gene promoter region and its clinical relevance to urocystic tumorigenesis.
|
| Sun XF, Li L, Li XJ, Shen W.
|
| Mol Biol Rep 39(8):8431-7. doi: 10.1007/s11033-012-1696-7. Epub 2012 Jun 19.
2012
|
| 13 | COSTS, HRAS
|
| Neonatal lethal Costello syndrome and unusual dinucleotide deletion/insertion mutations in HRAS predicting p.Gly12Val.
|
| Burkitt-Wright EM, Bradley L, Shorto J, McConnell VP, Gannon C, Firth HV, Park SM, D'Amore A, Munyard PF, Turnpenny PD, Charlton A, Wilson M, Kerr B.
|
| Am J Med Genet A 158A(5):1102-10. doi: 10.1002/ajmg.a.35296. Epub 2012 Apr 11.
2012
|
| 14 | COSTS, HRAS
|
| Costello syndrome: a Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations.
|
| Gripp KW, Lin AE.
|
| Genet Med 14(3):285-92. doi: 10.1038/gim.0b013e31822dd91f. Review.
2012
|
| 15 | HRAS, PEA15, PLD1
|
| PEA-15 potentiates H-Ras-mediated epithelial cell transformation through phospholipase D.
|
| Sulzmaier FJ, Valmiki MK, Nelson DA, Caliva MJ, Geerts D, Matter ML, White EP, Ramos JW.
|
| Oncogene 31(30):3547-60. doi: 10.1038/onc.2011.514. Epub 2011 Nov 21.
2012
|
| 16 | HRAS
|
| H-Ras isoform modulates extracellular matrix synthesis, proliferation, and migration in fibroblasts.
|
| Fuentes-Calvo I, Blázquez-Medela AM, Eleno N, Santos E, López-Novoa JM, Martínez-Salgado C.
|
| Am J Physiol Cell Physiol 302(4):C686-97. doi: 10.1152/ajpcell.00103.2011. Epub 2011 Nov 16.
2012
|
| 17 | DIRAS3, HRAS, RAF1
|
| The tumor suppressor DiRas3 forms a complex with H-Ras and C-RAF proteins and regulates localization, dimerization, and kinase activity of C-RAF.
|
| Baljuls A, Beck M, Oenel A, Robubi A, Kroschewski R, Hekman M, Rudel T, Rapp UR.
|
| J Biol Chem 287(27):23128-40. doi: 10.1074/jbc.M112.343780. Epub 2012 May 17.
2012
|
| 18 | HRAS, KRAS, SMPS1, SMPS2
|
| Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome.
|
| Groesser L, Herschberger E, Ruetten A, Ruivenkamp C, Lopriore E, Zutt M, Langmann T, Singer S, Klingseisen L, Schneider-Brachert W, Toll A, Real FX, Landthaler M, Hafner C.
|
| Nat Genet at Genet. 2012 2012
|
| 19 | BECN1, HRAS, PMAIP1
|
| Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival.
|
| Elgendy M, Sheridan C, Brumatti G, Martin SJ.
|
| Mol Cell 42(1):23-35. Epub 2011 Feb 25.
2011
|
| 20 | COSTS, HRAS
|
| Molecular confirmation of HRAS p.G12S in siblings with Costello syndrome.
|
| Gripp KW, Stabley DL, Geller PL, Hopkins E, Stevenson DA, Carey JC, Sol-Church K.
|
| Am J Med Genet A 155A(9):2263-8. doi: 10.1002/ajmg.a.34150. Epub 2011 Aug 10.
2011
|
| 21 | COSTS, HRAS
|
| HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome.
|
| Niihori T, Aoki Y, Okamoto N, Kurosawa K, Ohashi H, Mizuno S, Kawame H, Inazawa J, Ohura T, Arai H, Nabatame S, Kikuchi K, Kuroki Y, Miura M, Tanaka T, Ohtake A, Omori I, Ihara K, Mabe H, Watanabe K, Niijima S, Okano E, Numabe H, Matsubara Y.
|
| J Hum Genet 56(10):707-15. doi: 10.1038/jhg.2011.85. Epub 2011 Aug 18.
2011
|
| 22 | BRIP1, HRAS, KRAS
|
| Oncogenic RAS regulates BRIP1 expression to induce dissociation of BRCA1 from chromatin, inhibit DNA repair, and promote senescence.
|
| Tu Z, Aird KM, Bitler BG, Nicodemus JP, Beeharry N, Xia B, Yen TJ, Zhang R.
|
| Dev Cell 21(6):1077-91. doi: 10.1016/j.devcel.2011.10.010. Epub 2011 Dec 1.
2011
|
| 23 | BNIP3, HRAS
|
| H-ras up-regulates expression of BNIP3.
|
| Kalas W, Swiderek E, Rapak A, Kopij M, Rak J, Strzadala L.
|
| Anticancer Res 31(9):2869-75.
2011
|
| 24 | HRAS
|
| Identification of H-Ras-specific motif for the activation of invasive signaling program in human breast epithelial cells.
|
| Yong HY, Hwang JS, Son H, Park HI, Oh ES, Kim HH, Kim do K, Choi WS, Lee BJ, Kim HR, Moon A.
|
| Neoplasia 13(2):98-107.
2011
|
| 25 | HRAS
|
| Current evidence on the relationship between HRAS1 polymorphism and breast cancer risk: a meta-analysis.
|
| Zhang C, Lv GQ, Yu XM, Gu YL, Li JP, Du LF, Zhou P.
|
| Breast Cancer Res Treat 128(2):467-72. doi: 10.1007/s10549-011-1344-2. Epub 2011 Jan 9.
2011
|
| 26 | DPP8, DPP9, HRAS
|
| A novel role of dipeptidyl peptidase 9 in epidermal growth factor signaling.
|
| Yao TW, Kim WS, Yu DM, Sharbeen G, McCaughan GW, Choi KY, Xia P, Gorrell MD.
|
| Mol Cancer Res 9(7):948-59. doi: 10.1158/1541-7786.MCR-10-0272. Epub 2011 May 26.
2011
|
| 27 | COSTS, HRAS
|
| Duplication of Glu37 in the switch I region of HRAS impairs effector/GAP binding and underlies Costello syndrome by promoting enhanced growth factor-dependent MAPK and AKT activation.
|
| Gremer L, De Luca A, Merbitz-Zahradnik T, Dallapiccola B, Morlot S, Tartaglia M, Kutsche K, Ahmadian MR, Rosenberger G.
|
| Hum Mol Genet 19(5):790-802. Epub 2009 Dec 8.PMID: 19995790 2010
|
| 28 | DYRK1B, HRAS
|
| DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS.
|
| Lauth M, Bergström A, Shimokawa T, Tostar U, Jin Q, Fendrich V, Guerra C, Barbacid M, Toftgård R.
|
| Nat Struct Mol Biol 17(6):718-25. Epub 2010 May 30. 2010
|
| 29 | CSTS, HRAS
|
| Oncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome.
|
| Rosenberger G, Meien S, Kutsche K.
|
| Hum Mutat 30(3):352-62.
2009
|
| 30 | FGFR3, HRAS
|
| Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors.
|
| Goriely A, Hansen RM, Taylor IB, Olesen IA, Jacobsen GK, McGowan SJ, Pfeifer SP, McVean GA, Meyts ER, Wilkie AO.
|
| Nat Genet 41(11):1247-52. Epub 2009 Oct 25.PMID: 19855393 2009
|
| 31 | COSTS, HRAS
|
| Longitudinal course of cognitive, adaptive, and behavioral characteristics in Costello syndrome.
|
| Axelrad ME, Schwartz DD, Fehlis JE, Hopkins E, Stabley DL, Sol-Church K, Gripp KW.
|
| Am J Med Genet A 149A(12):2666-72.PMID: 19919001 2009
|
| 32 | HRAS, KRAS, BRAF, CFC2, COSTS, CFC3, MAP2K1, MAP2K2, CFC4, CFC5
|
| Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome.
|
| Schulz AL, Albrecht B, Arici C, van der Burgt I, Buske A, Gillessen-Kaesbach G, Heller R, Horn D, HŸbner CA, Korenke GC, Kšnig R, Kress W, KrŸger G, Meinecke P, MŸcke J, Plecko B, Rossier E, Schinzel A, Schulze A, Seemanova E, Seidel H, Spranger S, Tuysuz B, Uhrig S, Wieczorek D, Kutsche K, Zenker M.
|
| Clin Genet 73(1):62-70. Epub 2007 Nov 27. 2008
|
| 33 | COSTS, HRAS
|
| Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation.
|
| Denayer E, Parret A, Chmara M, Schubbert S, Vogels A, Devriendt K, Frijns JP, Rybin V, de Ravel TJ, Shannon K, Cools J, Scheffzek K, Legius E.
|
| Hum Mutat 29(2):232-9. 2008
|
| 34 | HRAS, COSTS
|
| Costello syndrome associated with novel germline HRAS mutations: an attenuated phenotype?
|
| Gripp KW, Innes AM, Axelrad ME, Gillan TL, Parboosingh JS, Davies C, Leonard NJ, Lapointe M, Doyle D, Catalano S, Nicholson L, Stabley DL, Sol-Church K.
|
| Am J Med Genet A 146(6):683-90. 2008
|
| 35 | COSTS, HRAS
|
| The diagnosis of Costello syndrome: nomenclature in Ras/MAPK pathway disorders.
|
| Kerr B, Allanson J, Delrue MA, Gripp KW, Lacombe D, Lin AE, Rauen KA.
|
| Am J Med Genet A 146A(9):1218-20. Review. No abstract available. 2008
|
| 36 | BRAF, CFC2, CFC3, CFC4, CFC5, COSTS, HRAS, KRAS, MAP2K1, MAP2K2, NS3
|
| The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
|
| Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y.
|
| Hum Mutat 29(8):992-1006.
2008
|
| 37 | BRAF, CFC2, CFC3, COSTS, HRAS, KRAS, LEOPS, MAP2K1, MAPK1, MTOR, NF1, NFNS, NS1, NS3, NS4, NS5, PTPN11, RAF1, SOS1
|
| Oncogenes on my mind: ERK and MTOR signaling in cognitive diseases.
|
| Krab LC, Goorden SM, Elgersma Y.
|
| Trends Genet 24(10):498-510. Epub 2008 Sep 4. 2008
|
| 38 | HRAS
|
| p21 Ras/impedes mitogenic signal propagation regulates cytokine production and migration in CD4 T cells.
|
| Czyzyk J, Chen HC, Bottomly K, Flavell RA.
|
| J Biol Chem 283(34):23004-15. Epub 2008 Jun 24.
2008
|
| 39 | HRAS, KRAS, NRAS
|
| Kras and Hras--what is the difference?
|
| Berns A.
|
| Nat Genet 40(10):1149-50. No abstract available.
2008
|
| 40 | CFC5, COSTS, HRAS, KRAS, NS3
|
| Clinical and molecular aspects of RAS related disorders.
|
| Denayer E, de Ravel T, Legius E.
|
| J Med Genet 45(11):695-703. Epub 2008 Jun 11. Review.
2008
|
| 41 | HRAS, COSTS
|
| HRAS and the Costello syndrome.
|
| Rauen K.
|
| Clin Genet 71(2):101-8. 2007
|
| 42 | NS3, KRAS, COSTS, HRAS
|
| The neoplastic risk in children with Noonan syndrome and Costello syndrome.
|
| Lopez-Rangel E.
|
| Clin Genet 71(1):44-5. 2007
|
| 43 | HRAS, COSTS
|
| Diversity, parental germline origin, and phenotypic spectrum of de novo HRAS missense changes in Costello syndrome.
|
| Zampino G, Pantaleoni F, Carta C, Cobellis G, Vasta I, Neri C, Pogna EA, De Feo E, Delogu A, Sarkozy A, Atzeri F, Selicorni A, Rauen KA, Cytrynbaum CS, Weksberg R, Dallapiccola B, Ballabio A, Gelb BD, Neri G, Tartaglia M.
|
| Hum Mutat 28(3):265-72. 2007
|
| 44 | CFC2, CFC3, CFC4, CFC5, KRAS, MAP2K1, MAP2K2, BRAF, COSTS, HRAS
|
| Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome.
|
| Narumi Y, Aoki Y, Niihori T, Neri G, Cave H, Verloes A, Nava C, Kavamura MI, Okamoto N, Kurosawa K, Hennekam RC, Wilson LC, Gillessen-Kaesbach G, Wieczorek D, Lapunzina P, Ohashi H, Makita Y, Kondo I, Tsuchiya S, Ito E, Sameshima K, Kato K, Kure S, Matsubara Y.
|
| Am J Med Genet A 143(8):799-807. 2007
|
| 45 | COSTS,HRAS
|
| Myopathy caused by HRAS germline mutations: implications for disturbed myogenic differentiation in the presence of constitutive HRas activation.
|
| van der Burgt I, Kupsky W, Stassou S, Nadroo A, Barroso C, Diem A, Kratz CP, Dvorsky R, Ahmadian MR, Zenker M.
|
| J Med Genet 44(7):459-62. Epub 2007 Apr 5. 2007
|
| 46 | CFC2, BRAF, CFC3, MAP21K1, CFC3, MAP2K2, CFC5, KRAS, COSTS, HRAS
|
| Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.
|
| Nava C, Hanna N, Michot C, Pereira S, Pouvreau N, Niihori T, Aoki Y, Matsubara Y, Arveiler B, Lacombe D, Pasmant E, Parfait B, Baumann C, HŽron D, Sigaudy S, Toutain A, Rio M, Goldenberg A, Leheup B, Verloes A, CavŽ H.
|
| J Med Genet 44(12):763-71. Epub 2007 Aug 17. 2007
|
| 47 | HRAS, COSTS
|
| HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation.
|
| Gripp KW, Lin AE, Stabley DL, Nicholson L, Scott CI Jr, Doyle D, Aoki Y, Matsubara Y, Zackai EH, Lapunzina P, Gonzalez-Meneses A, Holbrook J, Agresta CA, Gonzalez IL, Sol-Church K.
|
| Am J Med Genet A 140(1):1-7. 2006
|
| 48 | HRAS, COSTS
|
| HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy.
|
| Estep AL, Tidyman WE, Teitell MA, Cotter PD, Rauen KA.
|
| Am J Med Genet A 140(1):8-16. 2006
|
| 49 | HRAS, COSTS
|
| Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases.
|
| Kerr B, Delrue MA, Sigaudy S, Perveen R, Marche M, Burgelin I, Stef M, Tang B, Eden OB, O'Sullivan J, De Sandre-Giovannoli A, Reardon W, Brewer C, Bennett C, Quarell O, M'Cann E, Donnai D, Stewart F, Hennekam R, Cave H, Verloes A, Philip N, Lacombe D, Levy N, Arveiler B, Black G.
|
| J Med Genet 43(5):401-5. Epub 2006 Jan 27. 2006
|
| 50 | CFC2, BRAF, CFC3, MAP2K1, CFC4, MAP2K2, COSTS, HRAS
|
| Distinguishing Costello versus cardio-facio-cutaneous syndrome: BRAF mutations in patients with a Costello phenotype.
|
| Rauen KA.
|
| Am J Med Genet A 140(15):1681-3. No abstract available. 2006
|
| 51 | HRAS, COSTS
|
| Somatic mosaicism for an HRAS mutation causes Costello syndrome.
|
| Gripp KW, Stabley DL, Nicholson L, Hoffman JD, Sol-Church K.
|
| Am J Med Genet A 140(20):2163-9. 2006
|
| 52 | HRAS, CLU
|
| Oncogenic HRAS suppresses clusterin expression through promoter hypermethylation.
|
| Lund P, Weisshaupt K, Mikeska T, Jammas D, Chen X, Kuban RJ, UngethŸm U, Krapfenbauer U, Herzel HP, SchŠfer R, Walter J, Sers C.
|
| Oncogene 25(35):4890-903. Epub 2006 Mar 27. 2006
|
| 53 | HRAS, COSTS
|
| Germline mutations in HRAS proto-oncogene cause Costello syndrome.
|
| Aoki Y, Niihori T, Kawame H, Kurosawa K, Ohashi H, Tanaka Y, Filocamo M, Kato K, Suzuki Y, Kure S, Matsubara Y.
|
| Nat Genet 37(10):1038-40. Epub 2005 Sep 18. 2005
|
| 54 | ZDHHC9, GOLGA7, HRAS
|
| DHHC9 and GCP16 constitute a human protein fatty acyltransferase with specificity for H- and N-Ras.
|
| Swarthout JT, Lobo S, Farh L, Croke MR, Greentree WK, Deschenes RJ, Linder ME.
|
| J Biol Chem 280(35):31141-8. Epub 2005 Jul 6. 2005
|
| 55 | HRAS, RAP1A
|
| Identification of a novel domain of Ras and Rap1 that directs their differential subcellular localizations.
|
| Nomura K, Kanemura H, Satoh T, Kataoka T.
|
| J Biol Chem 279(21):22664-73. Epub 2004 Mar 18. 2004
|
| 56 | NRAS, KRAS, HRAS
|
| ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.
|
| Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J, Tallini G.
|
| J Clin Oncol 21(17):3226-35. 2003
|
| 57 | HRAS, KRAS, RCE1
|
| Human Ras converting enzyme endoproteolytic specificity at the P2' and P3' positions of K-Ras-derived peptides.
|
| Hollander IJ, Frommer E, Aulabaugh A, Mallon R.
|
| Biochim Biophys Acta 1649(1):24-9.
2003
|
| 58 | HRAS
|
| H-ras oncogene mutation in dedifferentiated liposarcoma. Polymerase chain reaction-restriction fragment length polymorphism analysis.
|
| Sakamoto A, Oda Y, Adachi T, Tamiya S, Matsuda S, Tanaka K, Iwamoto Y, Tsuneyoshi M.
|
| Am J Clin Pathol 115(2):235-42. 2001
|
| 59 | HRAS
|
| Additional characterization of a hexanucleotide polymorphic site in the first intron of human H-ras gene: comparative study of its alterations in non-small cell lung carcinomas and sporadic invasive breast carcinomas.
|
| Kotsinas A, Gorgoulis VG, Zacharatos P, Mariatos G, Kokotas S, Liloglou T, Ikonomopoulos J, Zoumpourlis V, Kyroudi A, Field JK, Asimacopoulos PJ, Kittas C.
|
| Cancer Genet Cytogenet 126(2):147-54. 2001
|
| 60 | HRAS
|
| Distinct mutation patterns of breast cancer-associated alleles of the HRAS1 minisatellite locus.
|
| Ding S, et al.
|
| Hum Mol Genet 8 : 515-521. 1999
|
| 61 | RASSF7, D11S4893, D11S4894, D11S4895, HRAS
|
| A 500-kb physical map and contig from the Harvey ras-1 gene to the 11p telomere.
|
| Russell MW, et al.
|
| Genomics 35 : 353-360. 1996
|
| 62 | HRAS, LQT1
|
| Molecular analysis at the Harvey Ras-1 gene in patients with long QT syndrome.
|
| Schulze-Bahr E, et al.
|
| J Mol Med 73 : 565-569. 1995
|
| 63 | HRAS, LQT1
|
| Exclusion of HRAS from long QT locus.
|
| Roy N, et al.
|
| Nat Genet 8 : 113-114. 1994
|
| 64 | HRAS
|
| Polymerase chain reaction analysis of allele frequency and loss at the Harvey ras locus in myeloid malignancies.
|
| Ardern JC, et al.
|
| Leukemia 7 : 258-262. 1993
|
| 65 | HRAS
|
| H-ras-1 gene mutations in basal cell carcinoma : automated direct sequencing of clinical specimens.
|
| Wilke WW, et al.
|
| Mod Pathol 6 : 15-19. 1993
|
| 66 | HRAS
|
| PCR detection of an insertion/deletion polymorphism in intron 1 of the HRAS1 locus.
|
| Tanci P, et al.
|
| Nucleic Acids Res 20 : 1157. 1992
|
| 67 | HRAS
|
| CGG repeat polymorphism at the c-Ha-ras oncogene locus.
|
| Riggins GJ, et al.
|
| Hum Mol Genet 1 : 775. 1992
|
| 68 | HRAS
|
| Prevalence of RAS oncogene mutation in head and neck carcinomas.
|
| Anderson JA, et al.
|
| J Otolaryngol 21 : 321-326. 1992
|
| 69 | HRAS, KRAS, NRAS
|
| Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas.
|
| Challen C, et al.
|
| J Hepatol 14 : 342-346. 1992
|
| 70 | HRAS
|
| Point mutations in the Ha-ras oncogene are detectable in formalin-fixed tissues of oral squamous cell carcinomas, but are infrequent in British cases.
|
| Warnakulasuriya KAAS, et al.
|
| J Oral Pathol Med 21 : 225-229. 1992
|
| 71 | HRAS
|
| Polymorphism in exon 1 of the c-Ha-ras gene, (HRAS).
|
| Hoban PR, et al.
|
| Nucleic Acids Res 19 : 6976. 1991
|
| 72 | HRAS
|
| Correlation of mutations of oncogene C-Ha-ras at codon 12 with metastasis and survival of gastric cancer patients.
|
| Deng G, et al.
|
| Oncogene Res 6 : 33-38. 1991
|
| 73 | HRAS
|
| A new RFLP in intron 1 of the human c-Ha-ras1 gene and its close relationship with the variable tandem repeats inthe region 3' to the gene.
|
| Iwahana H, et al.
|
| Oncogene 5 : 1049-1053. 1990
|
| 74 | HRAS
|
| A cosmid clone map derived from a small region of human chromosome 11.
|
| Harrison-Lavoie KJ, John RM, Porteous DJ, Little PF.
|
| Genomics 5 : 501-509. 1989
|
| 75 | HRAS
|
| RAS oncogene mutation in multiple myeloma.
|
| Neri A, et al.
|
| J Exp Med 170 : 1715-1725. 1989
|
| 76 | HRAS
|
| Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.
|
| Orita M, et al.
|
| Genomics 5 : 874-879. 1989
|
| 77 | HRAS, KRAS
|
| Analysis of RAS oncogene mutations in human lymphoid malignancies.
|
| Neri A, et al.
|
| Proc Natl Acad Sci U S A 85 : 9268-9272. 1988
|
| 78 | HRAS
|
| HinfI RFLP downstream to the human HRAS1 gene.
|
| Harumoto T, et al.
|
| Nucleic Acids Res 16 : 2366. 1988
|
| 79 | HRAS
|
| HRAS1-selected chromosome transfer generates markers which co-localize aniridia and genitourinary dysplasia associated translocation breakpoints and the Wilms' tumour gene within band 11p13.
|
| Porteous DJ, et al.
|
| (HGM9) Cytogenet Cell Genet 46 : 676. 1987
|
| 80 | HRAS, D11S99, D11S100, D11S101, D11S105, D11S106, D11S108, D11S109, D11S110, D11S111, D11S113, D11S115, D11S116, D11S117, D11S119, D11S169, D11S170, D11S171, D11S172, D11S173, D11S175, D11S176, D11S177, D11S178, D11S181
|
| Co-transfer of defined genes and cloning of anonymous DNA markers following HRAS1-selected chromosome mediated gene transfer.
|
| Porteous DJ, et al.
|
| (HGM9) Cytogenet Cell Genet 46 : 676. 1987
|
| 81 | HRAS
|
| Evidence against Ha-ras-1 involvement in sporadic and familial melanoma.
|
| Gerhard DS, et al.
|
| Nature 325 : 73-75. 1987
|
| 82 | HRAS
|
| Two RFLPs generated by Taq I at the human HRSA1 locus.
|
| Pierotti MA, et al.
|
| Nucleic Acids Res 14 : 4379. 1986
|
| 83 | HRAS
|
| Detection of two TaqI polymorphisms in the VTR region of the human HRAS1 oncogene.
|
| Pierotti MA, et al.
|
| Cytogenet Cell Genet 43 : 174-180. 1986
|
| 84 | INS, HRAS
|
| DNA polymorphisms indicate loss of heterozygosity for chromosome 11 of D98AH2 cells.
|
| Kaelbling M, et al.
|
| Cytogenet Cell Genet 41 : 240-244. 1986
|
| 85 | HRAS
|
| A dot-blot screening procedure for mutated ras oncogenes using synthetic oligodeoxynucleotides.
|
| Verlaan de Vries M, et al.
|
| Gene 50 : 313-320. 1986
|
| 86 | HB-NA@, HBB, HBBP1, HBD, HBE1, HBG1, HBG2, HRAS, INS, MODY10, PTH
|
| Germ-line chromosomal localization of genes in chromosome 11p linkage: parathyroid hormone, beta-globin, c-H-ras-1, and insulin.
|
| Chaganti RSK, et al.
|
| Somat Cell Mol Genet 11 : 197-202. 1985
|
| 87 | HRAS
|
| c-Ha-ras1 is not deleted in del(11p13) Wilms' tumor (WAGR) and maps to 11p15.1->11p15.5.
|
| Junien C, et al.
|
| (HGM7) Cytogenet Cell Genet 37 : 503. 1984
|
| 88 | HB-NA@, INS, WAGR, HRAS
|
| Wilms tumor-aniridia association : segregation of affected chromosome in somatic cell hybrids, identification of cell surface antigen associated with deleted area, and regional mapping of c-Ha-ras-1 oncogene, insulin gene, and beta-globin gene.
|
| Fisher JH, et al.
|
| Somat Cell Mol Genet 10 : 455-464. 1984
|
| 89 | HRAS, INS
|
| HRAS 1, insulin, and beta-globin map outside of 11p11.2-->p14.1
|
| de Martinville B, et al.
|
| (HGM7) Cytogenet Cell Genet 37 : 530. 1984
|
| 90 | HRAS, ERAS, KRAS1P, KRAS
|
| Dispersion of the ras family of transforming genes to four different chromosomes in man.
|
| O'Brien SJ, et al.
|
| Nature 302 : 839-842. 1983
|
| 91 | HRAS
|
| The c-Ha-ras 1, insulin, and beta-globin loci map outside the deletion associated with aniridia-Wilms' tumour.
|
| de Martinville B, et al.
|
| Nature 305 : 641-643. 1983
|
| 92 | HRAS
|
| Oncogene from human EJ bladder carcinoma is located on the short arm of chromosome 11.
|
| de Martinville B, et al.
|
| Science 219 : 498-501. 1983
|
| 93 | HRAS
|
| Localization of the normal allele of T24 human bladder carcinoma oncogene to chromosome 11.
|
| McBride I, et al.
|
| Nature 300 : 773-774. 1982
|